The Complexities of TGF-β Action During Mammary and Squamous Cell Carcinogenesis

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, California 94143-0512, USA.
Current pharmaceutical biotechnology (Impact Factor: 2.51). 05/2011; 12(12):2138-49. DOI: 10.2174/138920111798808284
Source: PubMed


Many advanced tumors produce excess amounts of Transforming Growth Factor-β (TGF-β), which is a potent growth inhibitor of normal epithelial cells. However, in tumors its homeostatic action on cells can be diverted along several alternative pathways. Thus, TGF-β signaling has been reported to elicit a preventative or tumor suppressive effect during the earlier stages of tumorigenesis, but later in tumor development, when carcinoma cells become refractory to TGF-β-mediated growth inhibition, response to TGF-β signaling elicits predominantly tumor progressing effects. This is not a simple switch from suppression to progression, but more like a rheostat, involving multiple complementary and antagonizing activities that slowly tip the balance from one to the other. This review will focus on the multiple activities of TGF-β in regulation of two epithelial tumor types, namely squamous cell carcinoma and breast cancer. Basic findings in current mouse models of cancer are presented, as well as a discussion of the complicating issue of outcome of altered TGFβ signaling depending on genetic variability between mouse strains. This review also discusses the role TGF-β within the tumor microenvironment particularly its ability to polarize the microenvironment towards a pro-tumorigenic milieu.

Download full-text


Available from: Rosemary J Akhurst, May 14, 2014
  • Source
    • "The survival of cancer cells in metastatic microenvironments and their further progression is regulated by complex interactions with non-tumor cells residing in or infiltrating into the tumor microenvironment such as endothelial cells, inflammatory cells and other immunocytes, bone marrow derived stem cells, adipocytes , and fibroblasts [48] [49] [50] [51] [52] [53] [54] [55]. This regulation is mediated through intricate signaling networks involving cytokines [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71], chemokines [31–36,38,43,44] and other molecules [72] [73] [74] [75] [76] [77] [78]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer cells that disseminate to metastatic sites may progress to frank metastasis or persist as dormant micrometastasis. Significant progress has been made in defining the genetic and phenotypic cancer-cell-autonomous determinants of metastasis and in the understanding of the cross-talk between metastasizing tumor cells and the metastatic microenvironment. However several questions remain open, in particular the identity of microenvironmental factors that keep micrometastatic cells in a state of dormancy and those that promote survival, proliferation and progression of such cells. Significantly more information is available on the latter factors than on microenvironmental cells and molecules that restrain micrometastasis. This mini-review summarizes findings suggesting that: •The interactions between the metastatic microenvironment and cancer cells metastasizing to this microenvironment are unique to each metastatic microenvironment.•cells or molecules in the metastatic microenvironment could act as "double agents" exerting pro- or anti-malignant functions.•In the early phases of tumor progression, the interactions between cancer cells and the metastatic microenvironment are inhibitory whereas in later stages such interactions promote progression towards metastasis. In view of the above, it is not unlikely that metastases residing in different microenvironments may require “individualized” treatment modalities.
    Cancer letters 08/2013; 352(1). DOI:10.1016/j.canlet.2013.08.029 · 5.62 Impact Factor
  • Source
    • "TGF-β signaling elicits a preventative or tumor suppressing effect during the earlier stages of tumorigenesis, when the epithelial cells retain exquisite growth sensitivity to this ligand. Later in tumor development, when carcinoma cells become refractory to TGF-β-mediated growth inhibition and acquire oncogenic mutations, the intracellular signaling circuitry of the cells is altered leading to tumor progressing effects, acting via an array of cellular and molecular mechanisms 17 (Figure 2). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Many advanced tumors produce excessive amounts of Transforming Growth Factor-β (TGF-β) which, in normal epithelial cells, is a potent growth inhibitor. However, in oncogenically activated cells, the homeostatic action of TGF-β is often diverted along alternative pathways. Hence, TGF-β signaling elicits protective or tumor suppressive effects during the early growth-sensitive stages of tumorigenesis. However, later in tumor development when carcinoma cells become refractory to TGF-β-mediated growth inhibition, the tumor cell responds by stimulating pathways with tumor progressing effects. At late stages of malignancy, tumor progression is driven by TGF-β overload. The tumor microenvironment is a target of TGF-β action that stimulates tumor progression via pro-tumorigenic effects on vascular, immune, and fibroblastic cells. Bone is one of the richest sources of TGF-β in the body and a common site for dissemination of breast cancer metastases. Osteoclastic degradation of bone matrix, which accompanies establishment and growth of metastases, triggers further release of bone-derived TGF-β. This leads to a vicious positive feedback of tumor progression, driven by ever increasing levels of TGF-β released from both the tumor and bone matrix. It is for this reason, that pharmaceutical companies have developed therapeutic agents that block TGF-β signaling. Nonetheless, the choice of drug design and dosing strategy can affect the efficacy of TGF-β therapeutics. This review will describe pre-clinical and clinical data of four major classes of TGF-β inhibitor, namely i) ligand traps, ii) antisense oligonucleotides, iii) receptor kinase inhibitors and iv) peptide aptamers. Long term dosing strategies with TGF-β inhibitors may be ill-advised, since this class of drug has potentially highly pleiotropic activity, and development of drug resistance might potentiate tumor progression. Current paradigms for the use of TGF-β inhibitors in oncology have therefore moved towards the use of combinatorial therapies and short term dosing, with considerable promise for the clinic.
    International journal of biological sciences 07/2012; 8(7):964-78. DOI:10.7150/ijbs.4564 · 4.51 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Agents targeting EGFR and related ErbB family proteins are valuable therapies for the treatment of many cancers. For some tumor types, including squamous cell carcinomas of the head and neck (SCCHN), antibodies targeting EGFR were the first protein-directed agents to show clinical benefit, and remain a standard component of clinical strategies for management of the disease. Nevertheless, many patients display either intrinsic or acquired resistance to these drugs; hence, major research goals are to better understand the underlying causes of resistance, and to develop new therapeutic strategies that boost the impact of EGFR/ErbB inhibitors. In this review, we first summarize current standard use of EGFR inhibitors in the context of SCCHN, and described new agents targeting EGFR currently moving through pre-clinical and clinical development. We then discuss how changes in other transmembrane receptors, including IGF1R, c-Met, and TGF-β, can confer resistance to EGFR-targeted inhibitors, and discuss new agents targeting these proteins. Moving downstream, we discuss critical EGFR-dependent effectors, including PLC-γ; PI3K and PTEN; SHC, GRB2, and RAS and the STAT proteins, as factors in resistance to EGFR-directed inhibitors and as alternative targets of therapeutic inhibition. We summarize alternative sources of resistance among cellular changes that target EGFR itself, through regulation of ligand availability, post-translational modification of EGFR, availability of EGFR partners for hetero-dimerization and control of EGFR intracellular trafficking for recycling versus degradation. Finally, we discuss new strategies to identify effective therapeutic combinations involving EGFR-targeted inhibitors, in the context of new system level data becoming available for analysis of individual tumors.
    Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy 09/2011; 14(6):260-79. DOI:10.1016/j.drup.2011.08.002 · 9.12 Impact Factor
Show more